D. Anderson Company Reports on 1st Quarter
Dallas
, Texas
- D. Anderson Company (DAC), an international patient recruitment and retention leader based in Dallas, posted a record first quarter on many fronts, including earnings, new business and requests for proposals. The privately held company, whose clientele is a who's who in pharmaceuticals and biotechnology, enters the second quarter brimming with optimism as contracts continue to outpace previous years.
Central to DAC's success is its growth in global markets and its ability to leverage 18 years of experience, including tenure as a Site Management Organization, niche Contract Research Organization and clinical trials recruitment provider.
"In 2007 and 2008, the percent of DAC's business with international focus was 40 and 48 percent respectively for the entire year," said DAC President and CEO Diana Anderson, Ph.D. "Already, in 2009, half of new contracts are for global programs, with the remaining focused on North America. Large pharmaceutical companies represent 66 percent of new business so far this year."
Dr. Anderson has positioned DAC as an international player with experience in 62 countries and expertise in more than 40 therapeutic areas. The company has strong roots in rheumatology but, today, draws most of its business from the oncology, cardiovascular, central nervous system, and immunology sectors.
DAC services include patient recruitment and retention, consulting, management, market research and customized training. With its full-service, in-house creative agency, DAC also combines messaging, design and branding to produce acclaimed marketing concepts.
About D. Anderson Company
With offices in Seattle, Houston and Dallas, DAC is a subsidiary of D.L. Anderson International. The company is certified as a Women-Owned Business (WBE) by the Women's Business Enterprise National Council and a continuing education provider through the California Board of Registered Nursing. For more information, visit
www.dandersoncompany.com
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Empower Sponsor Success with Insights from Sites
October 3rd 2024Are you tired of clinical trial technology that slows down processes? Are your sites looking for more intuitive solutions? At YPrime, we’ve taken a deep dive into site experiences and perspectives, sharing ways to bridge the gap between sponsors, sites, and patients, to foster a more efficient clinical trial process.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
New Survey Uncovers Distrust as Key Factor in Enrollment Declines Among Black Patients
October 2nd 2024Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.
Tulisokibart Shows Superior Efficacy in Achieving Clinical Remission for Ulcerative Colitis Patients
October 2nd 2024Proof-of-concept Phase II ARTEMIS-UC trial shows efficacy of investigational humanized monoclonal antibody tulisokibart in treating inflammatory bowel disease compared with placebo.
